The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.
 
Rajiv Shah
Honoraria - AstraZeneca; Janssen; Roche; Sanofi Aventis GmbH
Research Funding - Bristol Myers Squibb GmbH & Co.KGaA (Inst)
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Christian Grohe
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo
 
Daniel Christian Christoph
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ipsen; Janssen; MSD Sharp & Dohme; Novartis; Novocure; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ipsen; Janssen; MSD Sharp & Dohme; Novartis; Novocure; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ipsen; Janssen; MSD Sharp & Dohme; Novartis; Novocure; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Expert Testimony - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ipsen; Janssen; MSD Sharp & Dohme; Novartis; Novocure; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD Sharp & Dohme; Pfizer; Roche; Sanofi
 
Eva Lotte Buchmeier
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Takeda
Travel, Accommodations, Expenses - Janssen
 
Felix Carl Saalfeld
Honoraria - AstraZeneca; GWT; Novartis; Pfizer; Pfizer; Takeda; Thieme
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Janssen; Janssen; Pfizer
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Lilly; Takeda
 
Nikolaj Frost
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Berlin-Chemie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Sanofi/Aventis; Takeda
Research Funding - Roche Pharma AG
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Lilly; Roche Pharma AG; Takeda
(OPTIONAL) Uncompensated Relationships - Deutsche Forschungsgemeinschaft; Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistische Onkologie; German Society for Pneumology and Respiratory Medicine
 
Hans-Georg Kopp
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche; Sanofi/Aventis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Sanofi/Aventis
 
Martin Faehling
No Relationships to Disclose
 
Frank Griesinger
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis
Research Funding - AstraZeneca; Novartis
 
Julia Roeper
Honoraria - AstraZeneca
 
Petra Hoffknecht
No Relationships to Disclose
 
Jonas Kuon
Research Funding - AstraZeneca/MedImmune
 
Jingting Luan
No Relationships to Disclose
 
Paolo Chesi
No Relationships to Disclose
 
Petros Christopoulos
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)
 
Michael Thomas
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen Oncology; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda